Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 13/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23637706 | 0.92 | NR3C2 (0.51) | NR3C2MAPK14MAPK13LOXL2 | |
| SCHEMBL23637705 | 0.85 | NR3C2 (0.55) | NR3C2MAPK14MAPK13 | |
| SCHEMBL25641592 | 0.81 | MAPK14 (0.54) | NR3C2MAPK14MAPK13 | |
| SCHEMBL23637703 | 0.80 | MAPK14 (0.59) | NR3C2MAPK14MAPK13 | |
| SCHEMBL29166048 | 0.79 | NR3C2 (0.52) | NR3C2MAPK14 | |
| SCHEMBL20988697 | 0.76 | RIOK2 (0.54) | NR3C2 | |
| SCHEMBL20305452 | 0.74 | JAK2 (0.51) | NR3C2LOXL2 | |
| SCHEMBL25644194 | 0.74 | NR3C2 (0.48) | NR3C2MAPK14MAPK13 | |
| SCHEMBL16311110 | 0.73 | NR3C2 (0.52) | NR3C2MAPK14LOXL2 | |
| SCHEMBL23637709 | 0.72 | NR3C2 (0.57) | NR3C2MAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219489-A2 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | Washington University (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2023-06-22 | — | — | US | disclosed |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | NR3C2 1034/4885MAPK14 4/4885MAPK13 1/4885 |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | NR3C2 1034/4885MAPK14 4/4885MAPK13 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.